Relmada Therapeutics, Inc. RLMD Effective Income Tax Rate Reconciliation Tax Credits Research
Effective Income Tax Rate Reconciliation Tax Credits Research at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch.
The official record: Relmada Therapeutics, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s effective income tax rate reconciliation tax credits research.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s effective income tax rate reconciliation tax credits research?
- Relmada Therapeutics, Inc. (RLMD) reported effective income tax rate reconciliation tax credits research of 1.4% in Q4 2025.
- What does effective income tax rate reconciliation tax credits research mean?
- The impact of research and development tax credits on the effective tax rate, expressed as a percentage of pre-tax income. It quantifies the relative benefit of R&D incentives in lowering the company's overall tax expense.